Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial

Kazuhiro Yoshida; Yasuhiro Kodera; Mitsugu Kochi; Wataru Ichikawa; Yoshihiro Kakeji; Takeshi Sano; Narutoshi Nagao; Masazumi Takahashi; Akinori Takagane; Takuya Watanabe; Masahide Kaji; Hiroshi Okitsu; Takashi Nomura; Takanori Matsui; Takaki Yoshikawa; Jin Matsuyama; Makoto Yamada; Seiji Ito; Masahiro Takeuchi; Masashi Fujii

doi:10.1200/jco.18.01138

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

Addition of docetaxel to S-1 is effective with few safety concerns in patients with stage III gastric cancer. The present findings may also be applicable in countries in which perioperative adjuvant chemotherapy or chemoradiation is not standard.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Yoshida et al. (2019) studied this question.

synapsesocial.com/papers/69d750edb54ccf0cfef30db0 https://doi.org/10.1200/jco.18.01138

View Full Paper

Ask AI

Bookmark

Share

Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial

Ask about this paper

Abstract

Discussion

Cite This Study

Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC-07, a Randomized Controlled Trial

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading